Effect of intensive and standard pitavastatin treatment with or without eicosapentaenoic acid on progression of coronary artery calcification over 12 months

Prospective multicenter study

PEACH Investigators

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression. Methods and Results: This prospective multicenter study in Japan included patients with an Agatston score of 1–999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups. The primary outcome was the annual percent change in Agatston score in all patients. In total, 156 patients who had multi-detector row computed tomography without any artifacts were included in the primary analysis. Pitavastatin did not significantly reduce the annual progression rate of the Agatston score (40%; 95% CI: 19–61%). The annual progression rate of Agatston score in the PIT2 group was not significantly different from that in the PIT4 group (34% vs. 42%, respectively; P=0.88) or the PIT2+EPA group (34% vs. 44%, respectively; P=0.80). On post-hoc analysis the baseline ratio of low- to high-density lipoprotein cholesterol was a significant predictor of non-progression of Agatston score by pitavastatin (OR, 2.17; 95% CI: 1.10–44.12; P=0.02). Conclusions: Pitavastatin does not attenuate progression of CAC. Intensive pitavastatin treatment and standard treatment with EPA does not reduce progression of CAC compared with standard treatment.

Original languageEnglish
Pages (from-to)532-540
Number of pages9
JournalCirculation Journal
Volume82
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Eicosapentaenoic Acid
Multicenter Studies
Coronary Vessels
Prospective Studies
Therapeutics
Hypercholesterolemia
Artifacts
HDL Cholesterol
pitavastatin
Japan
Cardiovascular Diseases
Tomography
Lipids

Keywords

  • Calcification
  • Computed tomography
  • Eicosapentaenoic acid
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{bea3491811fd4a1eb8533bc8e1635b85,
title = "Effect of intensive and standard pitavastatin treatment with or without eicosapentaenoic acid on progression of coronary artery calcification over 12 months: Prospective multicenter study",
abstract = "Background: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression. Methods and Results: This prospective multicenter study in Japan included patients with an Agatston score of 1–999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups. The primary outcome was the annual percent change in Agatston score in all patients. In total, 156 patients who had multi-detector row computed tomography without any artifacts were included in the primary analysis. Pitavastatin did not significantly reduce the annual progression rate of the Agatston score (40{\%}; 95{\%} CI: 19–61{\%}). The annual progression rate of Agatston score in the PIT2 group was not significantly different from that in the PIT4 group (34{\%} vs. 42{\%}, respectively; P=0.88) or the PIT2+EPA group (34{\%} vs. 44{\%}, respectively; P=0.80). On post-hoc analysis the baseline ratio of low- to high-density lipoprotein cholesterol was a significant predictor of non-progression of Agatston score by pitavastatin (OR, 2.17; 95{\%} CI: 1.10–44.12; P=0.02). Conclusions: Pitavastatin does not attenuate progression of CAC. Intensive pitavastatin treatment and standard treatment with EPA does not reduce progression of CAC compared with standard treatment.",
keywords = "Calcification, Computed tomography, Eicosapentaenoic acid, Statin",
author = "{PEACH Investigators} and Toru Miyoshi and Kunihisa Kohno and Hirohiko Asonuma and Satoru Sakuragi and Makoto Nakahama and Yusuke Kawai and Tadahisa Uesugi and Takefumi Oka and Mitsuru Munemasa and Natsuki Takahashi and Naoki Mukohara and Seiji Habara and Yasushi Koyama and Kazufumi Nakamura and Hiroshi Itoh",
year = "2018",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-17-0419",
language = "English",
volume = "82",
pages = "532--540",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "2",

}

TY - JOUR

T1 - Effect of intensive and standard pitavastatin treatment with or without eicosapentaenoic acid on progression of coronary artery calcification over 12 months

T2 - Prospective multicenter study

AU - PEACH Investigators

AU - Miyoshi, Toru

AU - Kohno, Kunihisa

AU - Asonuma, Hirohiko

AU - Sakuragi, Satoru

AU - Nakahama, Makoto

AU - Kawai, Yusuke

AU - Uesugi, Tadahisa

AU - Oka, Takefumi

AU - Munemasa, Mitsuru

AU - Takahashi, Natsuki

AU - Mukohara, Naoki

AU - Habara, Seiji

AU - Koyama, Yasushi

AU - Nakamura, Kazufumi

AU - Itoh, Hiroshi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression. Methods and Results: This prospective multicenter study in Japan included patients with an Agatston score of 1–999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups. The primary outcome was the annual percent change in Agatston score in all patients. In total, 156 patients who had multi-detector row computed tomography without any artifacts were included in the primary analysis. Pitavastatin did not significantly reduce the annual progression rate of the Agatston score (40%; 95% CI: 19–61%). The annual progression rate of Agatston score in the PIT2 group was not significantly different from that in the PIT4 group (34% vs. 42%, respectively; P=0.88) or the PIT2+EPA group (34% vs. 44%, respectively; P=0.80). On post-hoc analysis the baseline ratio of low- to high-density lipoprotein cholesterol was a significant predictor of non-progression of Agatston score by pitavastatin (OR, 2.17; 95% CI: 1.10–44.12; P=0.02). Conclusions: Pitavastatin does not attenuate progression of CAC. Intensive pitavastatin treatment and standard treatment with EPA does not reduce progression of CAC compared with standard treatment.

AB - Background: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression. Methods and Results: This prospective multicenter study in Japan included patients with an Agatston score of 1–999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups. The primary outcome was the annual percent change in Agatston score in all patients. In total, 156 patients who had multi-detector row computed tomography without any artifacts were included in the primary analysis. Pitavastatin did not significantly reduce the annual progression rate of the Agatston score (40%; 95% CI: 19–61%). The annual progression rate of Agatston score in the PIT2 group was not significantly different from that in the PIT4 group (34% vs. 42%, respectively; P=0.88) or the PIT2+EPA group (34% vs. 44%, respectively; P=0.80). On post-hoc analysis the baseline ratio of low- to high-density lipoprotein cholesterol was a significant predictor of non-progression of Agatston score by pitavastatin (OR, 2.17; 95% CI: 1.10–44.12; P=0.02). Conclusions: Pitavastatin does not attenuate progression of CAC. Intensive pitavastatin treatment and standard treatment with EPA does not reduce progression of CAC compared with standard treatment.

KW - Calcification

KW - Computed tomography

KW - Eicosapentaenoic acid

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85041028694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041028694&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-17-0419

DO - 10.1253/circj.CJ-17-0419

M3 - Article

VL - 82

SP - 532

EP - 540

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 2

ER -